Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218034 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT02218034: Completed Phase 1 study, sponsored by Allergan.
NCT02218034 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 78 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02218034, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
Interventions
- DRUG AGN-190168 Formulation 1
- DRUG AGN-190168 Formulation 2
- DRUG tazarotene gel 0.1%
- DRUG tazarotene cream 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
What the finished NCT02218034 record still lists
NCT02218034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 4 interventions - of which AGN-190168 Formulation 1 is the first listed.
NCT02218034 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02218034 about?
NCT02218034 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris". This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
What is the current status of trial NCT02218034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2014-08. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02218034?
The interventions under investigation include: AGN-190168 Formulation 1 (DRUG), AGN-190168 Formulation 2 (DRUG), tazarotene gel 0.1% (DRUG), tazarotene cream 0.1% (DRUG).
Who is sponsoring clinical trial NCT02218034?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02218034's enrollment target sits among peer trials
78 697th of 2000 higher than 1,298 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia